OA10648A - Azetidinone derivatives for the treatment of atherosclerosis - Google Patents

Azetidinone derivatives for the treatment of atherosclerosis Download PDF

Info

Publication number
OA10648A
OA10648A OA70172A OA70172A OA10648A OA 10648 A OA10648 A OA 10648A OA 70172 A OA70172 A OA 70172A OA 70172 A OA70172 A OA 70172A OA 10648 A OA10648 A OA 10648A
Authority
OA
OAPI
Prior art keywords
oxoazetidin
diastereoisomer
benzylsulphinyl
ylacetamide
acetamide
Prior art date
Application number
OA70172A
Other languages
English (en)
Inventor
Dashyant Dhanak
Deirdre Mary Bernadette Hickey
Robert John Ife
Colin Andrew Leach
David Graham Tew
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9513442.5A external-priority patent/GB9513442D0/en
Priority claimed from GBGB9515056.1A external-priority patent/GB9515056D0/en
Priority claimed from GBGB9515206.2A external-priority patent/GB9515206D0/en
Priority claimed from GBGB9516985.0A external-priority patent/GB9516985D0/en
Priority claimed from GBGB9525132.8A external-priority patent/GB9525132D0/en
Priority claimed from GBGB9608651.7A external-priority patent/GB9608651D0/en
Priority claimed from GBGB9608650.9A external-priority patent/GB9608650D0/en
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of OA10648A publication Critical patent/OA10648A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D205/00Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/06Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D205/08Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D205/00Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/06Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D205/08Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
    • C07D205/085Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams with a nitrogen atom directly attached in position 3
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D205/00Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/06Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D205/08Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
    • C07D205/09Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams with a sulfur atom directly attached in position 4
    • C07D205/095Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams with a sulfur atom directly attached in position 4 and with a nitrogen atom directly attached in position 3
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
OA70172A 1995-07-01 1997-12-31 Azetidinone derivatives for the treatment of atherosclerosis OA10648A (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GBGB9513442.5A GB9513442D0 (en) 1995-07-01 1995-07-01 Novel compounds
GBGB9515056.1A GB9515056D0 (en) 1995-07-22 1995-07-22 Novel compounds
GBGB9515206.2A GB9515206D0 (en) 1995-07-25 1995-07-25 Novel compounds
GBGB9516985.0A GB9516985D0 (en) 1995-08-18 1995-08-18 Novel compounds
GBGB9525132.8A GB9525132D0 (en) 1995-12-08 1995-12-08 Novel compounds
GBGB9608651.7A GB9608651D0 (en) 1996-04-26 1996-04-26 Novel compounds
GBGB9608650.9A GB9608650D0 (en) 1996-04-26 1996-04-26 Novel compounds

Publications (1)

Publication Number Publication Date
OA10648A true OA10648A (en) 2002-09-25

Family

ID=27562921

Family Applications (1)

Application Number Title Priority Date Filing Date
OA70172A OA10648A (en) 1995-07-01 1997-12-31 Azetidinone derivatives for the treatment of atherosclerosis

Country Status (23)

Country Link
EP (1) EP0840725A1 (fr)
JP (1) JP2002515852A (fr)
KR (1) KR19990028630A (fr)
CN (1) CN1197452A (fr)
AP (1) AP728A (fr)
AU (1) AU708032B2 (fr)
BG (1) BG102214A (fr)
BR (1) BR9609445A (fr)
CA (1) CA2225627A1 (fr)
CZ (1) CZ422197A3 (fr)
EA (1) EA199800109A1 (fr)
HU (1) HUP9901153A3 (fr)
IL (1) IL122650A0 (fr)
MA (1) MA23922A1 (fr)
MX (1) MX9800186A (fr)
NO (1) NO976158L (fr)
NZ (1) NZ311684A (fr)
OA (1) OA10648A (fr)
PE (1) PE8998A1 (fr)
PL (1) PL324240A1 (fr)
SK (1) SK178497A3 (fr)
TR (1) TR199701762T1 (fr)
WO (1) WO1997002242A1 (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0869943A1 (fr) * 1995-12-08 1998-10-14 Smithkline Beecham Plc Derives de beta-lactame monocycliques utilises dans le traitement de l'atherosclerose
CZ341098A3 (cs) * 1996-04-26 1999-03-17 Smithkline Beecham Plc Azetidinonové deriváty pro ošetřování aterosklerózy
GB9608649D0 (en) * 1996-04-26 1996-07-03 Smithkline Beecham Plc Novel compounds
PL209824B1 (pl) * 2000-02-16 2011-10-31 Smithkline Beecham Plc 1-(N-2-(dietyloamino)etylo)-N-(4-(4-trifluorometylo-fenylo)benzylo)aminokarbonylometylo)-2-(4-fluorobenzylo)tio-5,6-trimetylenopirymidyn-4-on, jego zastosowania i zawierająca go farmaceutyczna kompozycja
GB0024808D0 (en) 2000-10-10 2000-11-22 Smithkline Beecham Plc Novel compounds
US8962633B2 (en) 2007-05-11 2015-02-24 Thomas Jefferson University Methods of treatment and prevention of metabolic bone diseases and disorders
KR101563753B1 (ko) 2007-05-11 2015-10-27 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 피부 궤양의 치료 방법
KR101461659B1 (ko) 2007-05-11 2014-11-17 토마스 제퍼슨 유니버시티 신경변성 질환 및 장애의 치료 및 예방 방법
SG190830A1 (en) 2010-12-06 2013-07-31 Glaxo Group Ltd Pyrimidinone compounds for use in the treatment of diseases or conditions mediated by lp - pla2
WO2012080497A2 (fr) 2010-12-17 2012-06-21 Glaxo Group Limited Procédés de traitement et de prévention de maladies oculaires
CN103619831B (zh) 2011-06-27 2016-05-04 中国科学院上海药物研究所 唑类杂环化合物、其制备方法、药物组合物和用途
AU2012289492B2 (en) 2011-07-27 2016-02-04 Glaxo Group Limited 2,3-dihydroimidazo[1,2-c] pyrimidin-5(1H)-one compounds use as Lp-PLA2 inhibitors
CA2843102A1 (fr) 2011-07-27 2013-01-31 Glaxo Group Limited Composes pyrimidones bicycliques
AU2014210259B2 (en) 2013-01-25 2016-11-03 Glaxosmithkline Intellectual Property Development Limited Compounds
JP2016505053A (ja) 2013-01-25 2016-02-18 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited Lp‐PLA2の阻害剤としての二環式ピリミドン化合物
JP6306053B2 (ja) 2013-01-25 2018-04-04 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited 2,3−ジヒドロイミダゾール[1,2−c]ピリミジン−5(1H)−オンに基づくリポタンパク質関連ホスホリパーゼA2(Lp−PLA2)阻害剤
WO2016012917A1 (fr) 2014-07-22 2016-01-28 Glaxosmithkline Intellectual Property Development Limited Dérivés 1,2,3,5-tétrahydro-imidazo [1,2-c]pyrimidine utiles pour le traitement de maladies et de troubles médiés par la lp-pla2
WO2016012916A1 (fr) 2014-07-22 2016-01-28 Glaxosmithkline Intellectual Property Development Limited Dérivés 1,2,3,5-tétrahydro-imidazo [1,2-c]pyrimidine utiles pour le traitement de maladies et de troubles médiés par la lp-pla2
PE20230092A1 (es) 2019-11-09 2023-01-16 Shanghai Simr Biotechnology Co Ltd Derivado triciclico de dihidroimidazopirimidona, metodo de preparacion del mismo, composicion farmaceuticas y uso del mismo
CN115304620A (zh) 2021-05-07 2022-11-08 上海赛默罗生物科技有限公司 嘧啶酮衍生物、其制备方法、药物组合物和用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4680391A (en) * 1983-12-01 1987-07-14 Merck & Co., Inc. Substituted azetidinones as anti-inflammatory and antidegenerative agents
NZ228600A (en) * 1988-04-11 1992-02-25 Merck & Co Inc 1-(benzylaminocarbonyl)-4-phenoxy-azetidin-2-one derivatives
IL99658A0 (en) * 1990-10-15 1992-08-18 Merck & Co Inc Substituted azetidinones and pharmaceutical compositions containing them
GB9421816D0 (en) * 1994-10-29 1994-12-14 Smithkline Beecham Plc Novel compounds
NZ298416A (en) * 1994-12-22 1999-03-29 Smithkline Beecham Plc Substituted azetidin-2-one derivatives and medicaments thereof

Also Published As

Publication number Publication date
PE8998A1 (es) 1998-03-20
JP2002515852A (ja) 2002-05-28
EP0840725A1 (fr) 1998-05-13
AP9701161A0 (en) 1998-01-31
WO1997002242A1 (fr) 1997-01-23
EA199800109A1 (ru) 1998-10-29
TR199701762T1 (xx) 1998-05-21
AP728A (en) 1999-01-29
NZ311684A (en) 2000-04-28
CN1197452A (zh) 1998-10-28
CZ422197A3 (cs) 1998-06-17
HUP9901153A3 (en) 1999-11-29
MX9800186A (es) 1998-07-31
AU6305096A (en) 1997-02-05
KR19990028630A (ko) 1999-04-15
MA23922A1 (fr) 1996-12-31
BG102214A (en) 1998-08-31
SK178497A3 (en) 1998-07-08
AU708032B2 (en) 1999-07-29
NO976158L (no) 1998-02-25
NO976158D0 (no) 1997-12-30
BR9609445A (pt) 1999-04-06
IL122650A0 (en) 1998-08-16
HUP9901153A2 (hu) 1999-08-30
CA2225627A1 (fr) 1997-01-23
PL324240A1 (en) 1998-05-11

Similar Documents

Publication Publication Date Title
OA10648A (en) Azetidinone derivatives for the treatment of atherosclerosis
US5990102A (en) Substituted azetidin-2-ones for treatment of atherosclerosis
US6071899A (en) Azetidinone derivatives for the treatment of atherosclerosis
JPH0329789B2 (fr)
EP0915843A1 (fr) Derives azetidinones destines au traitement de l'atherosclerose
FR2462428A1 (fr) Derives d'acide dithioacyldihydropyrazole carboxylique, derives de dithioacylproline, et composes apparentes, a action antihypertensive
EP0900199A1 (fr) Derives d'azetidinone pour le traitement de l'atherosclerose
EA021484B1 (ru) Азетидиноновые соединения и медицинское применение указанных соединений
IL104122A (en) Aromatic esters of phenylenedialkanoates, process for their preparation, pharmaceutical compositions containing them and their use as inhibitors of human neutrophil elastase
HU208671B (en) Process for producing of pyrrolidine derivatives and pharmaceutical preparations containing these compounds
US4849419A (en) 7-oxo-4-thia-azabicyclo[3,2,0]hept-2-ene derivatives
JPS58134074A (ja) 抗菌剤、その製法及びそれを含む医薬組成物
JPH0780840B2 (ja) 4,4‐ジアルキル‐2‐アゼチジノン類の製造法
FR2551441A1 (fr) Derives de aminomethyl-2-penem, leur procede de preparation et les preparations pharmaceutiques
FR2552763A1 (fr) Nouveaux derives du carbapeneme, leur preparation et leur utilisation comme medicaments
JPH0316357B2 (fr)
JP3175857B2 (ja) 1β−置換カルバペネム合成中間体
FR2541279A1 (fr) Derives de l'acide 1-aza-7-oxo-bicyclo(3.2.0)-hept-2-ene-2-carboxylique
HU198066B (en) Process for producing 2-(1-oxo-3-thiolanyl)-2-penem antibiotics
SK29295A3 (en) 4-oxo-azetidine-2-sulphonic acid amides and their salts, process for their production and their use
MXPA98008924A (en) Azetidinone derivatives for deeterosclero treatment
JPS63264453A (ja) アゼチジノン誘導体
JPH0565291A (ja) (3S、4R)−3−[1(R)−(t−ブチルジメチルシリルオキシ)エチル−4−[1−オキソ−3−チオールアニルチオ(チオカルボニル)チオアゼチジン−2−オンおよびこれらのための中間体の改良された製造方法